BIOSINT jest znakiem towarowym zastrzeonym przez Sigma-Tau HealthScience USA
Traditional formulations often suffer from issues like: Poor encapsulation of sensitive or water-repelling (hydrophobic) actives Inconsistent particle size, leading to unpredictable bioavailability and targeting Rapid degradation or leakage, resulting in short shelf life Difficulties maintaining performance when scaling from lab to production Liposome encapsulation solves these problems by: Maximizes absorption, especially for oral and topical delivery Extends circulation time for longer therapeutic effect Minimizes toxicity through targeted or controlled release Shields fragile actives such as mRNA, enzymes, and probiotics from degradation At BOC Sciences, we address these obstacles head-on through advanced liposome encapsulation technology
Research Disclaimer:Products are for laboratory and scientific research only and are not intended for human consumption, veterinary use, clinical application, or therapeutic treatment
1136-A LIVER TRANSPLANTATION MANAGES ELEXACAFTOR/TEZACAFTOR/IVACAFTOR LIVER INJURY, AND IMPROVES PULMONARY FUNCTION, WITHOUT RECURRENCE OF LIVER INJURY DESPITE RESUMPTION OF THERAPY FOLLOWING TRANSPLANTATION Richard Gilroy 1 , Sophie Hansen 1,2 , Holly Rupone 2 and Laurie LeClair 2 , (1)Intermountain Health, (2)University of Utah Background: Cystic fibrosis (CF) is a potentially lethal inherited disease caused by mutations of the CF transmembrane conductance regulator (CFTR) gene
